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QUALITY OF LIFE IS SEVERELY COMPROMISED IN
ADULT PATIENTS WITH ATOPIC DERMATITIS IN
BRAZIL, ESPECIALLY DUE TO MENTAL
COMPONENTS
Silvana Coghi1, Maria Cecilia Bortoletto1, S.A.P. Sampaio1, Heitor Franco de
Andrade Junior2, Valeria Aoki1
Coghi S, Bortoletto MC, Sampaio SAP, Andrade Junior HF, Aoki V. Quality of life is severely compromised in adult
patients with atopic dermatitis in Brazil, especially due to mental components. Clinics. 2007;62(3):235-42.
PURPOSE: to measure the quality of life (QoL), either by a specific dermatology or generic self applied questionnaire, in Atopic
dermatitis adult Brazilian patients, looking for selected affected groups.
METHODS: We studied the quality of life of 75 Brazilian ambulatory adults with atopic dermatitis using two types of self-
answered instruments: a quality of life generic questionnaire (SF-36) and a 10-item Dermatology Life Quality Index (DLQI)
questionnaire. All patients had been treated for at least 6 months, and their disease status was determined by Eczema Area and
Severity Index scores.
RESULTS: Quality of life and disease control were found to be related but with low scores both in DLQI (r2=0.26) and in SF-36
(r2=0.20), but with greater correlation for SF-36 mental components. Using the 75% percentile distribution of SF36 mean score
and the 75% value of disease severity score, we sorted patients into four groups: I, referring good QoL and mild atopic disease (14/
75), II, referring bad QoL and with mild atopic disease (19/75), III referring good QoL despite severe atopic disease (5/75) and IV
referring bad QoL and severe atopic disease (37/75); all groups presented similar age, education, family income and time of
disease progression. There was a higher frequency of women in group II, but without sleep disturbance or increased pruritus,
which was present in group IV, with intense itching and sleep disturbances. Analyzing the physical or mental components of the
SF36 generic test, discrepant groups II and III presented higher differences related to the mental components of the test, which
was also related to DLQI scores, with a similar distribution for the 2 groups and a higher relation to the mental component of the
generic test.
CONCLUSION: The quality of life is affected in adult atopic patients, both related to disease severity and also to mental
components, but with diverse effects in patient subgroups. Our data show some components that may mask the exact relationship
between QoL results and disease severity.
KEY WORDS: Atopic dermatitis; Quality of life; Quality of life questionnaire; Dermatology; Quality questionnaire.
INTRODUCTION
Atopic dermatitis (AD) is a pruritic, chronic, inflam-
matory skin condition, with wide-ranging clinical presen-
tation, which affects 2-7% of the adult population and 10
to 15% of children1. Its prevalence has increased in recent
years, doubling each decade2. In most individuals the dis-
ease begins in infancy but steadily abates throughout child-
hood, with some patients remaining severely affected
throughout their teenage years and adult life3, with a re-
sulting impact in adult patient life4. This impact of atopic
dermatitis in adults is so intense that it affects their qual-
ity of life, resulting in a stronger perception of the sever-
ity of disease when compared with psoriasis patients5. This
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pattern of adult atopic dermatitis leads to psychosocial dis-
turbances in most patients, especially of self-image, and
the persistence of the condition may continue to damage
patients’ self-esteem, their ability to cope with the disease
and adherence to therapy6. The impact of skin lesions due
to visible aspects has huge psychological implications and
thus it is strongly advisable for the dermatologist to evalu-
ate the quality of life of the atopic patient7. Studies have
identified problems such as feelings of shame or embar-
rassment, anxiety, low confidence and problems with per-
sonal, social and work relationships8. The assessment of
major mood disturbances as anxiety, depression, mood
changes, self-esteem or stigmatization were also found in
adult AD patients9,10, indicating that the individual response
of most patients is related to the disease.
Atopic dermatitis is usually chronic, and its treatment
demands a high level of patient compliance11. Several of
the treatments are not innocuous to the patients, meaning
that a careful risk-benefit decision must be made before in-
troducing potentially harmful drugs, such as cyclosporin
A12. In the decision-making process, the clinical picture is
easily assessed by clearly devised standardized protocols,
as the EASI, but other aspects of the patient’s life, such as
its quality, are not so easily measurable13. Most studies re-
porting evaluation of quality of life in dermatology patients
use questionnaire-based tests, as the Dermatology Life
Quality Index (DLQI), Psoriasis Disability Index (PDI), UK
Sickness Impact Profile (UKSIP) and Eczema Disability
Index (EDI)14. Most studies show the relationship between
disease severity and quality of life but all systems present
problems. The most usual problem is the adaptation of a
general questionnaire to a skin disease, as in the case of
the SF36 test15. Specific tests have been developed for skin
diseases, such as the DLQI or the VQ-Dermato, but some
of them were tailored for specific cultural settings and thus
may not be fully suited for other populations16,17.
The most usual feature of these tests is the agreement
between their measurement of quality of life and the clini-
cal presentation of the disease, but this agreement presents
low defined impact, as usually expressed by r2 values lower
than 0.5 in most descriptions. The impact of a skin dis-
ease on quality of life is usually more significant for the
patient than the risk imposed by the disease itself18, which
could explain the low agreement.
Some events may be responsible for those characteris-
tics and affect evaluation of the response to the question-
naire, which, in turn, must be adequate for evaluating pa-
tient evolution or therapy effect, if the improvement of
quality of life is being considered as a treatment goal.
We analyzed the quality of life by two questionnaire-
based instruments administered to adult Brazilian patients
with atopic dermatitis, one generic and the other disease-
related, dissecting their components in those patients, regard-
ing the impact of disease severity in their quality of life, look-
ing for specific factors that could affect this measure.
METHODS
Sample Population and clinical analysis.
This study was conducted at the Outpatient Dermatol-
ogy Clinic which is part of the General Hospital of the
School of Medicine of the University of São Paulo (Hos-
pital das Clínicas da Faculdade de Medicina da
Universidade de São Paulo), a large, 3200-bed teaching-
training hospital in São Paulo, Brazil. The study was ap-
proved by the Institutional Ethics Committee. Patients were
diagnosed and treated as isolated atopic dermatitis by the
attending clinician, and were sent for interview during their
treatment. Each patient was thoroughly informed; those
who agreed to participate gave their written consent. Illit-
erate and <18 year old patients were excluded. EASI scores
were determined at this time, when each participant an-
swered the DLQI and SF36 questionnaires alone and in a
quiet room, without interruptions. The sample was collected
between January and July of 2004, with 75 patients with
atopic dermatitis diagnosed according to the reported cri-
teria 21, with demographic and EASI data and complete
DLQI and SF36 questionnaires. Disease severity was as-
sessed by Eczema Area and Severity Index (EASI), which
involves an assessment of disease extent on a scale of 0 to
6 in 4 defined body regions (head/neck, upper limbs, trunk,
lower limbs) plus an evaluation of erythema, infiltration
and/or papulation, excoriation, and lichenification, each on
a scale of 0 to 3. The sum of these scores composed the
EASI index, which ranged from 0, or no disease, to 72, or
maximum disease 22.
Quality of life assessment. Quality of life was evalu-
ated through two questionnaire-based tests: a generic (SF-
36) and a specific dermatology instrument (DLQI). The
Medical Outcomes Study 36- Item Short- Form Health Sur-
vey (SF-36) is a self-administered, multidimensional, widely
used and well-validated generic instrument. Questions per-
tain to the individual’s typical routine day, the past four
weeks and experiences in general. The SF- 36 comprises 36
items, with 1 Physical (PCS-36) and 1 Mental (MCS- 36)
Component Summary Score, based on specific 8 domains
scores, from 0 to 100, combined into a physical and mental
scale. Alternatively, a mean value of all domains was also
used, ranging from 0, worst, to 100, the best quality of life.
This questionnaire has shown satisfactory reliability and va-
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lidity and has been tested for psychometric properties in sev-
eral countries, including Brazil 23.
The Dermatology Life Quality Index (DLQI) is a sim-
ple, compact, dermatology-specific test, applicable to pa-
tients with any skin disease. It measures how much a skin
problem has affected the life of the patient over the previ-
ous 7 days: it consists of 10 items, 6 dimensions and 1 over-
all summary score, and ranges between 0 (the best score)
and 30 (the worst score). The 6 dimensions are:1) Symp-
toms and feelings; 2) Daily activities; 3) Leisure; 4) Work
and school; 5) Personal relationships, and 6) Treatment.
DLQI is being used in studies of patients with many skin
diseases 18.
Grouping patients according to their referred QoL
and disease severity. We sorted patients according to their
mean quantitative SF36 value and EASI score. Patients
were defined as having a better quality of life when their
scores fell into the 25% highest percentile in the SF 36
mean domain scores distribution of all patients, which is a
cut-off value of 80. Disease severity was also defined us-
ing the same rationale, resulting in a cut-off value of 18
for this score; patients were sorted as having a mild dis-
ease when their EASI score was lower than 18 and as hav-
ing a severe disease when EASI was higher than 18. These
cut-off values defined four groups: group I with patients
with EASI less than 18 and mean SF-36 score over 80,
group II with patients with EASI scores lower than 18 and
mean SF36 lower than 80, group III with patients with
EASI scores over 18 and mean SF-36 score over 80 and
group IV with patients with EASI scores over 18 and mean
SF-36 score lower than 80.
Statistical analysis. All demographic data were submit-
ted to descriptive statistics for random distribution confir-
mation. The relation between disease indexes and quality
of life indexes were performed using Pearson correlation,
expressed by r2 when significant. Sorted groups of patients,
using mean SF36 values and EASI scores, were compared
for their demographic and clinical data using chi-square
test, and DLQI and SF-36 domains quantitative data of
sorted groups were compared with ANOVA or Kruskal-
Wallis tests, according to variance homegeneity. Data was
considered different or significant when the probability of
equality was less than 0.05 (p<0.05). Data was analyzed
using Statistica 4.0 software.
RESULTS
The demographic data of 75 patients enrolled in the
study show the usual gender distribution: 26/75 (34,6%)
were male and 49/75 (65,4%) were female, similar to the
usual sex distribution in atopic dermatitis8. Age varied from
18 to 53, with a mean of 26 years. Ethnic background was
found to be 50% white, 15% black and 35% miscigenated
on the basis of patients’ self-definitions. The time gap be-
tween diagnosis of atopic dermatitis and administration of
the quality of life test ranged between 8 months to 50 years,
with a mean of 17 years. All patients were middle class
urban citizens; 11% had attended only elementary school,
68% high school and 21% had achieved university degree,
without bias related to mean family income. Mean scores
were: 24.10 (S.D. = 17.7) for EASI, 5.89 (S.D. = 3.06) for
itching, and 3.89 (S.D. = 3.72) for insomnia.
Quality of life and disease severity. The distribution
of disease severity, expressed as EASI score, and quality
of life, measured both by a generic SF-36 test or specific
DLQI test, of our patients can be seen in Fig. 1.
There is a good relationship between QoL and clinical
disease severity expressed as EASI in both tests (p<0.001),
slightly better with DLQI test (r2=0,26) than with mean SF36
(r2=0,19), but a large fraction of the patients reported a low
QoL, despite mild disease and some patients reported good
QoL despite severe skin disease. We analyzed the physical
and mental components of the SF-36 test and their relation-
ship with disease severity as can be seen in Fig. 2, showing
that the mental component presents lower correlation with
disease severity than the physical components, in spite of a
higher dispersion of both components in this disease.
Patients were sorted into 4 groups according to their
EASI and SF-36 values as specified in Methods (Figure 3).
There were 14/75 (18.6%) concordant patients referring
good Qol with mild AD (group I); 19/75 (25.3%) discord-
Figure 1 - Distribution of mean scores of Quality of life tests according to
disease severity (EASI) in AD adult patients in Brazil. Closed circles: mean
value of SF36 domains Open circles DLQI scores. Line shows linear
regression of each QoL test. Tables shows correlation between tests and
disease severity, both with p<0.001)
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ant patients referring bad QoL with mild AD (group II); 5/
75 (6.6%) discordant patients referring good QoL despite
severe AD (group III) and 37/75 (49.3%) concordant pa-
tients referring bad QoL with severe AD (group IV).
The distribution according to the specific DLQI test was
similar to the sorting with the generic SF-36 (Figure 4),
an expected finding as the 2 tests are clearly associated.
All patients were comparable in terms of age, educa-
tion, family income and time of disease progression, as
shown in table 1. Sex distribution was similar in isolated
groups, as shown in Table 1, but group II presented a higher
female ratio, as compared with all others groups together
(p<0.05), as shown in Figure 5.
Patient distribution according mental and physical
components. We analyzed the physical and mental indi-
vidual components of SF-36 according to the sorted groups,
as shown in Figure 6. The physical component studied,
composed by Physical Function, Role-Physical Function,
Body pain and General Health perception domains, showed
the same pattern of effects on quality of life and disease
severity, usually severely affected in group IV as a conse-
quence of disease severity. The mental component, com-
posed by Vitality, Mental Health, Social function, and, es-
pecially, Role-Emotional Function domains were most af-
fected and were quite dissimilar between sorted groups,
showing a great difference between disease severity and
quality of life scores. Regarding the mental component,
group II was quite similar to group IV, while group I was
similar to group III. The mental component appears to have
a great impact on the mean of quality of life scoring.
We also evaluated the scores for some specific symp-
toms, such as intensity of pruritus and insomnia, and the
distribution of those scores in the sorted groups, as shown
in Figure 8. Regarding pruritus, the groups presented a
broad distribution according to disease severity, group I
with lower counts and group IV with higher counts. Sleep
disturbances presented a different pattern, with all groups
showing a relatively large number of patients without sleep
disturbances; however, group III differed from group IV,
which showed a large number of patients with sleep dis-
turbances, while patients from group III despite the same
disease severity showed less sleep disturbances.
Figure 2 - Distribution and correlation with 95% intervals of mean values
of physical (closed circles and dashed line) and mental (open circles and
solid line) components of the SF-36 generic QoL test in AD adults Brazilian
patients as related to disease severity, expressed by EASI scores. Table shows
values of r2, all data significant (p<0.001)
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Figure 3 - Selection of subgroups according disease severity, as expressed
by EASI scores, and QoL, as expressed by mean domains SF36 values.
Dashed areas used for better visualization.
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Table 1. Demographic data in AD adult patients, sorted by subgroups
Total Group
Sample I II III IV
Gender as % females(females/total) 65.33(49/75) 71.4(4/14) 84.21(3/19) 60(3/5) 54.05(20/37
Age in years(mean ± SD) 26.28±8.98 25.64±8.68 26.80±10.76 27±8.15 26.11±8.53
Family income(Min.Wage±SD) 6.34±0.89 5.57±6.81 6.05±11.73 5.40±3.84 6.91±6
Education (Semiquantitativescore±SD) 2.57±0.14 2.14±0.95 2.42±1.21 2.00±0 2.89±1.28
Duration of disease(years±SD) 16.74±1.26 13.2±8.73 18.57±14.49 11.80±9.33 17.78±9.62
All groups presents no significant differences with ANOVA test
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DISCUSSION
Our data clearly show that atopic dermatitis in adulthood
severely affects QoL of most patients, as described both by
a generic test, the SF36, or by a specific dermatology DLQI
test. This fact is in agreement with studies comparing atopic
dermatitis and other chronic diseases, 22 apart from the fact
that atopic dermatitis has an increasing prevalence in this
adult age group II5,26. Thus its effects on QoL justifies more
aggressive therapies, in order to avoid stigmatization or so-
cial problems. Despite the higher costs of aggressive therapy,
the resulting improvement in QoL indirectly supports the in-
tervention. Our data in AD patients are similar to reported
QoL analysis in other populations. In those reports, AD pa-
tients also presented higher DLQI scores as compared to pso-
riatic patients, another chronic dermatological affection. Our
data suggest that AD patients present more mental effects
of the disease in QoL, as demonstrated by lower scores in
social and emotional domains in the SF36 tests, a point also
made in other reports 11,16,27,28. In one of these studies, the
DLQI mean score was lower, at 7.3, than in our group, which
presented 9.97 as mean value; this was also discrepant from
the 5.93 mean value of psoriasis patients 27. This discrep-
ancy could be attributed to Brazilian cultural aspects; alter-
natively, it may be due to a more restrictive sample selec-
tion in our study, using patients with more severe disease;
or a more accurate definition of disease severity, by the EASI
score, as the disease severity in the previous study was self
evaluated, which could be also affected by mental aspects
27
. Another aspect was the younger age of our patients and
the longer treatment period, as compared to reported data.
Figure 4 - Quality of life measured by specific dermatological test DLQI, in
groups segregated according to methods and fig.3. Bars represent the mean
values of each group. Inserted table shows statistical comparison between
groups, with (*) marking post-test significance.
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Figure 5 - Female predominance in group II when compared with joined
populations of other groups. Table shows Chi-square values and significance.
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Figure 6 - Distribution of mean values of physical (A) and mental (B) components in the QoL SF36 tests of AD adult Brazilian patients, segregated by
groups according methods and fig.3. Table shows analysis of variance and post-hoc comparison (Dunns test) between segregated groups.
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The older population could also be more adapted to AD, due
to age or social stabilization, or to the development of cop-
ing mechanisms 28,29. Our data is also similar to a study re-
porting QoL in psoriasis patients, also analyzed by a Jalowiec
Coping Scale and a specific Psoriasis Disability Index (PDI)
which showed a crucial mental effect in QoL evaluation.
Similar to our findings, the SF-36 mental domains correlated
positively to QoL, as opposed to negatively related mental
health and QoL 29. AD appears to the patient as a restrictive
disease, interfering in daily activities, and specially in so-
cial and interpersonal relationships, severely impacting emo-
tional aspects of the patients 11,12,30. This bad QoL effect of
AD was also found when compared to several other derma-
tological diseases, in a standardization report of DLQI test
18
, also related to disease severity in which the impact of AD
on QoL was higher than other severe dermatological dis-
eases, as psoriasis 5.
Our study clearly shows that there was general agree-
ment between disease severity and quality of life in the
whole sample of atopic dermatitis patients. This agreement
was unrelated to the two questionnaires used, SF36 and
DLQI, which turned out in very good agreement. This find-
ing was also noted by others, evaluating 239 AD patients,
including 107 adults, with worse quality of life, defined by
SF-36 and DLQI indexes, related to disease severity25. Sig-
nificant correlation between feeling of stigmatization and
disease severity, measured by the Severity Scoring of At-
opic dermatitis (SCORAD) was also found more frequently
in patients with AD than with psoriasis 10. Children with
AD had the quality of life inversely correlated with dis-
ease severity evaluated by Children’s Dermatology Life
Quality Index (CDLQI) and SCORAD, especially in the
first visits 29. The discrepancy of our data in suggesting
some specific grouping in the sample was also suggested
by others, specially in psoriasis when objective Psoriasis
Area Severity Index(PASI) is evaluated, without correla-
tion with QoL self assessment 32. This correlation was at-
tributed to some subgroups present in low numbers in the
whole population which affect the main response of the
sample. Such hypothesis agrees with the apparent data dis-
persion in those studies and could also explain several re-
ports that did not find agreement between disease severity
and quality of life, as described in studies about the effects
of cyclosporin A on atopic dermatitis 20.
In the present study, we found some subgroups which
described their quality of life on the basis of the mental com-
ponent, leading to patients being described as better QoL in
spite of a severe disease or as bad QoL with mild disease.
Interestingly, a study investigating the relationship between
anxiety and the severity of AD by DLQI using normal hos-
pital staff for comparison, found a correlation between DLQI
and severity of AD (r=0.54). However, anxiety levels, as
scored by STAI, had no relationship with disease severity
33
. The absence of association between medical skin disease
evaluation and patient self assessment was also shown dur-
ing autologous blood therapy in atopic dermatitis 34. In 51
patients suffering from dermatological disorders, a correla-
tion between physician score and DLQI (r2=0.306) was dem-
onstrated, but with differences if the disease was scored by
the patient, as expressed by DLQI, or by disease morbidity
as scored by the physician 35. Similarly to our sub-group-
ing, it was suggested, in the latter study, that patients who
are not very sick could overestimate their disease, while more
affected dermatological patients underestimated their own
disease as compared with their physician. Our findings of
gender differences, with women predominance, in group II,
was similar to elsewhere reported findings, with females be-
ing much more aware and critical to external lesions in at-
opic disease, as compared to men 11,36.
Additionally, the analysis of physical and mental com-
ponents in the SF-36 questionnaires clearly shows that the
mental component is the most impacting for scores of qual-
Figure 7 - Major symptoms analysis as pruritus(A) and sleep disturbances(B), evaluated by semiquantative scores as described in Methods, in AD Brazilian
adult patients, segregated according methods and fig. 3. Bar represents mean value and table shows ANOVA analysis. (*) marks significant post hoc group.
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ity of life. In view of their higher frequency in our group
II of bad QL and mild patients, women are probably more
prone to refer bad QoL due to atopic dermatitis, in the pres-
ence of a mild disease, a finding also reported elsewhere
and which was attributed to self-esteem and related aspects
36,37
. There are also other reports referring to optimistic or
pessimistic patients with polarized self evaluation in QoL
tests, which could be also more accurately found with our
grouping system 29. When quality of life is assessed, the
underlying mental aspects may affect its measure, and we
have clearly shown this in our sorted groups. How this bias
affects the measurement of quality of life is a matter of
debate and newer tests and groups should be tested for elu-
cidation. In fact, we believe that such aspects are inbuilt
into any quality of life questionnaire-based test and can-
not be easily removed. The solution could be the introduc-
tion of filters of those domains which are more emotion-
ally affected, and also quoting their ratio with some physi-
cal domains that could measure the optimism or pessimism
of each individual patient, correcting QoL for the under-
lying emotional status of the patient.
Apart from describing the huge effect of AD in QoL of
adult patients, we devised a simple sorting method which
allows the discrimination of emotional status and reveals
the presence of subgroups in a large sample. We are aware
that our proposition as it stands is rather simple and should
be improved by choosing a non orthogonal model, but our
data has produced promising results. The distinct response
of such patients must be studied in order to obtain a cor-
rect and unbiased interpretation of their quality of life.
 RESUMO
Coghi S, Bortoletto MC, Sampaio SAP, Andrade Junior HF,
Aoki V. A qualidade de vida é muito comprometida em
pacientes adultos com dermatite atópica no Brasil,
especialmente devido a fatores emocionais. Clinics.
2007;62(3):235-42.
OBJETIVOS: Medir a qualidade de vida (QoL), por
questionários tanto genéricos como dermatológicos
específicos, em pacientes adultos brasileiros com dermatite
atópica, procurando por grupos afetados selecionados.
MÉTODOS: Nós estudamos a qualidade de vida em 75
pacientes brasileiros adultos em tratamento ambulatorial de
dermatite atópica, usando dois tipos de questionários de
auto-resposta, previamente padronizados: um questionário
genérico de qualidade de vida de 36 questões (SF-36) e um
questionário de 10 questões para determinação do índice
dermatológico de qualidade de vida (DLQI). Todos os
pacientes estavam em tratamento por pelo menos seis meses
e o seu estágio de doença clinico definido quantitativamente
pelo índice padronizado de gravidade e áreas de eczema
(EASI).
RESULTADOS: A QoL e o controle da doença estavam
relacionados mas com baixa relação tanto avaliados pelo
DLQI (r2=0.26) ou pelo SF-36 (r2=0.20), mas com maiores
relações com os componentes emocionais do SF-36.
Usando a distribuição do percentil 75% para o SF36 e os
valores de 75% do escore de gravidade clínica EASI, os
pacientes foram distribuídos em quatro grupos: I que referia
boa QoL e doença atópica leve (14/75), II referindo má
QoL e doença atópica leve (19/75), III referindo boa QoL
apesar de doença atópica mais grave (5/75) e IV
concordando uma má QoL referida e uma doença atópica
mais grave (37/75); todos os grupos apresentavam mesma
distribuição etária, educação e nível social, renda familiar
e tempo de doença. Havia uma maior freqüência de
mulheres no grupo II, mas sem distúrbios de sono ou
prurido intenso, fatores presentes intensamente no grupo
IV. Dissecando os componentes físicos e emocionais do
SF36, os grupos discrepantes II e II apresentavam maior
diferença relativa aos componentes emocionais do teste,
que também estavam relacionados aos valores do teste
DLQI, o qual apresentava uma distribuição similar entre
os grupos e maior relação aos componentes emocionais do
teste genérico.
CONCLUSÕES: A qualidade de vida é afetada em
pacientes adultos com dermatite atópica, relacionada tanto
com a gravidade da doença clinica como com os
componentes emocionais, que são diferentes em subgrupos
de pacientes. Estes dados mostram componentes que podem
mascarar o exato impacto da severidade da doença sobre a
qualidade de vida destes pacientes.
UNITERMOS: Dermatite atópica; Dualidade de vida; SF-
36; DLQI.
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